Document Format Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
1 | F-1 | tm2225088-21_f1.htm | F-1 | 5592818 |
2 | EXHIBIT 3.1 | tm2225088d22_ex3-1.htm | EX-3.1 | 451534 |
3 | EXHIBIT 3.2 | tm2225088d22_ex3-2.htm | EX-3.2 | 259167 |
4 | EXHIBIT 4.2 | tm2225088d22_ex4-2.htm | EX-4.2 | 6690 |
5 | EXHIBIT 5.1 | tm2225088d22_ex5-1.htm | EX-5.1 | 32745 |
6 | EXHIBIT 10.1 | tm2225088d22_ex10-1.htm | EX-10.1 | 79732 |
7 | EXHIBIT 10.2 | tm2225088d22_ex10-2.htm | EX-10.2 | 59287 |
8 | EXHIBIT 10.3 | tm2225088d22_ex10-3.htm | EX-10.3 | 257297 |
9 | EXHIBIT 10.4 | tm2225088d22_ex10-4.htm | EX-10.4 | 352008 |
10 | EXHIBIT 10.5 | tm2225088d22_ex10-5.htm | EX-10.5 | 160944 |
11 | EXHIBIT 10.6 | tm2225088d22_ex10-6.htm | EX-10.6 | 439739 |
12 | EXHIBIT 10.7 | tm2225088d22_ex10-7.htm | EX-10.7 | 156726 |
13 | EXHIBIT 10.8 | tm2225088d22_ex10-8.htm | EX-10.8 | 140440 |
14 | EXHIBIT 10.9 | tm2225088d22_ex10-9.htm | EX-10.9 | 148510 |
15 | EXHIBIT 21.1 | tm2225088d22_ex21-1.htm | EX-21.1 | 4998 |
16 | EXHIBIT 23.1 | tm2225088d22_ex23-1.htm | EX-23.1 | 2456 |
17 | EXHIBIT 99.1 | tm2225088d22_ex99-1.htm | EX-99.1 | 59478 |
18 | EXHIBIT 99.2 | tm2225088d22_ex99-2.htm | EX-99.2 | 51945 |
19 | EXHIBIT 99.3 | tm2225088d22_ex99-3.htm | EX-99.3 | 3536 |
20 | EXHIBIT 99.4 | tm2225088d22_ex99-4.htm | EX-99.4 | 3407 |
21 | EXHIBIT 99.5 | tm2225088d22_ex99-5.htm | EX-99.5 | 2387 |
22 | EXHIBIT 99.6 | tm2225088d22_ex99-6.htm | EX-99.6 | 3430 |
23 | EXHIBIT 99.7 | tm2225088d22_ex99-7.htm | EX-99.7 | 3533 |
24 | EX-FILING FEES | tm2225088d22_ex-filingfees.htm | EX-FILING FEES | 22003 |
25 | GRAPHIC | fc_ourcorporate-bw.jpg | GRAPHIC | 184045 |
26 | GRAPHIC | lc_antitumor-4clr.jpg | GRAPHIC | 138275 |
27 | GRAPHIC | lg_adlainortye-4c.jpg | GRAPHIC | 24298 |
28 | GRAPHIC | tm2225088d1-fc_platform4c.jpg | GRAPHIC | 150732 |
29 | GRAPHIC | tm2225088d1-lc_activate4clr.jpg | GRAPHIC | 49124 |
30 | GRAPHIC | tm2225088d1-lc_activity4clr.jpg | GRAPHIC | 97646 |
31 | GRAPHIC | tm2225088d1-lc_antitum4clr.jpg | GRAPHIC | 279086 |
32 | GRAPHIC | tm2225088d1-lc_combinat4clr.jpg | GRAPHIC | 162450 |
33 | GRAPHIC | tm2225088d1-lc_data4clr.jpg | GRAPHIC | 131803 |
34 | GRAPHIC | tm2225088d1-lc_effects4clr.jpg | GRAPHIC | 129268 |
35 | GRAPHIC | tm2225088d1-lc_immunec4clr.jpg | GRAPHIC | 86893 |
36 | GRAPHIC | tm2225088d1-lc_model4clr.jpg | GRAPHIC | 144856 |
37 | GRAPHIC | tm2225088d1-lc_sensitve4clr.jpg | GRAPHIC | 80969 |
38 | GRAPHIC | tm2225088d1-lc_summary4clr.jpg | GRAPHIC | 151375 |
39 | GRAPHIC | tm2225088d1-lc_survival4clr.jpg | GRAPHIC | 115579 |
40 | GRAPHIC | tm2225088d1-lc_treat4clr.jpg | GRAPHIC | 177648 |
41 | GRAPHIC | tm2225088d1-lc_triple4c.jpg | GRAPHIC | 232423 |
42 | GRAPHIC | tm2225088d1-pht_action4c.jpg | GRAPHIC | 226083 |
43 | GRAPHIC | tm2225088d1-pht_dendrit4clr.jpg | GRAPHIC | 144005 |
44 | GRAPHIC | tm2225088d1-pht_head4clr.jpg | GRAPHIC | 99868 |
45 | GRAPHIC | tm2225088d1-pht_mechan4clr.jpg | GRAPHIC | 95869 |
46 | GRAPHIC | tm2225088d1-pht_mechani4c.jpg | GRAPHIC | 242350 |
47 | GRAPHIC | tm2225088d1-pht_ration4c.jpg | GRAPHIC | 226649 |
48 | GRAPHIC | tm2225088d1-pht_tech4c.jpg | GRAPHIC | 226819 |
49 | GRAPHIC | tm2225088d1-tbl_pipelin4c.jpg | GRAPHIC | 267446 |
50 | GRAPHIC | tm2225088d1-tbl_summary4clr.jpg | GRAPHIC | 206202 |
51 | GRAPHIC | tm2225088d18_ex5-1img001.jpg | GRAPHIC | 5286 |
52 | GRAPHIC | tm2225088d18_ex99-2img001.jpg | GRAPHIC | 3694 |
53 | GRAPHIC | txt_adlainorty-bw.jpg | GRAPHIC | 19984 |
54 | GRAPHIC | txt_hangzhou-bw.jpg | GRAPHIC | 15164 |
55 | GRAPHIC | txt_shanghi-bw.jpg | GRAPHIC | 21129 |
Complete submission text file | 0001104659-23-084478.txt | 13835757 |
IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: F-1 | Act: 33 | File No.: 333-273465 | Film No.: 231115129
SIC: 2834 Pharmaceutical Preparations